Hospira responds to FDA crticism

Pharmaceutical company Hospira has responded to US Food and Drug Administration claims of regulatory violations at its Melbourne plant. 

The Hospira plant received an FDA warning letter in September following an inspection.

In a statement sent to Pharmacy News, the company said: